Monkeypox Vaccine Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     Global Monkeypox 
Vaccine Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
Accord ing  to  the  la tes t  repor t  by  IMARC Group ,  t i t led  "Monkeypox Vacc ine  
Market :  Globa l  Industry  Trends,  Share ,  S ize ,  Growth,  Oppor tun i ty  and 
Forecast  2024-2032 ,"  t he  g loba l  monkeypox  vacc ine  marke t  s i ze  reached  US$ 
86 .6  Mi l l ion  in  2023 .
Report Factors Af fect ing the Growth of  the Monkeypox Vaccine Industry:
Global  Heal th In i t iat ives and Funding Increases:
Highlight and The r ise  in  in te rna t iona l  focus  on  in fec t ious  d i seases  is  d r iv ing  the  demand fo r  
vacc ines  aga ins t  emerg ing  th rea ts  l i ke  monkeypox .  Governments ,  g loba l  
hea l th  bod ies ,  and  p r i va te  en t i t i es  a re  inc reas ing ly  inves t ing  in  vacc ine  
Description deve lopment  and  d is t r ibu t ion  f rameworks  to  p reven t  w idespread  ou tb reaks .  
Th is  r i se  in  fund ing  no t  on ly  fac i l i t a tes  the  acce le ra ted  deve lopment  and  
approva l  o f  new vacc ines  bu t  a lso  enhances  the  manu fac tu r ing  capab i l i t i es  o f  
pharmaceu t ica l  compan ies .  As  a  resu l t ,  t he  capac i ty  to  p roduce  vacc ines  a t  
sca le  and  the  ab i l i t y  t o  rap id l y  respond  to  emerg ing  hea l th  c r i ses  a re  marked ly  
improv ing .
Rising Incidence of  Monkeypox Cases:
The not iceable  increase in  monkeypox cases across mul t ip le  reg ions 
g lobal ly  is  suppor t ing the growth of  the market .  Th is  upt ick  is  l inked to  
severa l  fac tors ,  inc lud ing greater  human in teract ion wi th  an imal  vectors 
Report and in ternat ional  t rave l ,  which fac i l i ta tes  the cross-border  t ransmiss ion of  the v i rus.  
The growing awareness among publ ic  heal th  author i t ies  and surve i l lance 
Highlight and of  monkeypox are lead ing to  improved d iagnosis  ra tes,  subsequent ly  
increasing the perce ived need for  vaccinat ion.  The urgent  demand for  
Description ef fec t ive prevent ive measures against  a  potent ia l  outbreak encourages 
heal thcare systems and governments  to  procure and s tockp i le  adequate 
vacc ine suppl ies .
Advancements in Vaccine Technology:
Recent  technolog ica l  advancements  in  vacc ine research and development  
(R&D) are bo ls ter ing the market  growth.  Innovat ions,  such as messenger  
r ibonuc le ic  ac id  (mRNA)  vaccine technology,  are be ing adapted for  o ther  
in fect ious d iseases,  inc lud ing monkeypox.
These  techno log ies  a l l ow fo r  qu icker  deve lopment  and  po ten t ia l l y  more  
e f fec t i ve  vacc ines ,  i nc reas ing  the i r  adop t ion  ra te .  Moreove r ,  the  ab i l i t y  t o  
ad jus t  ex is t ing  p la t fo rms  to  ta rge t  new pa thogens  reduces  the  t ime  and  cos t  
assoc ia ted  w i th  vacc ine  deve lopment ,  mak ing  the  p rocess  more  e f f i c ien t  and  
Report sca lab le .  Th is  fac to r  no t  on ly  enhances  the  p roduc t ion  capac i t y  o f  vacc ine  manufac tu re rs  bu t  a l so  improves  the  g loba l  read iness  to  comba t  emerg ing  
in fec t ious  d iseases .
Highlight and 
Request  for  a  PDF sample  o f  th is  repor t :  
Description h t tps : / /www. imarcgroup .com/monkeypox-vacc ine-marke t / requestsamp le
Report Description
Global  Monkeypox Vaccine Market Trends:
Increased publ ic  awareness about  monkeypox and i ts  t ransmiss ion dynamics p lays a s igni f icant  ro le  in  
dr iv ing vacc ine demand.  As awareness grows,  so does the w i l l i ngness  of  the publ ic  to  receive 
vacc inat ions,  in f luenced by targeted hea l th communicat ion s t rategies and publ ic  heal th campaigns.  
Fur thermore,  governments implement ing robust  heal th pol ic ies that  inc lude vacc inat ion programs as par t  
o f  the i r  d isease prevent ion and contro l  p lans  a lso spur  market  growth.  
These po l ic ies of ten mandate  vacc ine procurement  and adminis t rat ion,  supported by pub l ic  heal th  
adv isor ies and educat iona l  campaigns that  e f fec t ive ly  increase communi ty  engagement  and compl iance.  
Thus,  in formed publ ic  behavior  combined wi th  proact ive  governmental  s t ra teg ies enhances the overa l l  
demand for  monkeypox vacc ines.
View Report  TOC, Figures and Tables :  ht tps: / /www.imarcgroup.com/monkeypox-vaccine-market
Breakup by Type:
• Repl icat ion-competent
• Repl icat ion-defi cient
Breakup by Route of Administration:
• Subcutaneous
Report • Percutaneous
Segmentation
Breakup by Distribution Channel:
• Hospita l  Pharmacy
• Retai l  Pharmacy
• Onl ine Pharmacy
• Others
Breakup by End User:
• Hospitals
• Clinics
• Others
Report Breakup by Region:
• North America
Segmentation
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
How big is the global monkeypox vaccine market?
What is the expected growth rate of the global 
monkeypox vaccine market during 2024-2032?
What are the key factors driving the global 
Key monkeypox vaccine market?
Questions What has been the impact of COVID-19 on the 
global monkeypox vaccine market?
Answered in What is the breakup of the global monkeypox 
vaccine market based on the route of 
the Report administration?
What is the breakup of the global monkeypox 
vaccine market based on the distribution channel?
What is the breakup of the global monkeypox 
vaccine market based on end user?
What are the key regions in the global monkeypox 
vaccine market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  M o n k e y p o x  V a c c i n e  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  T y p e
    6 . 1     R e p l i c a t i o n - c o m p e t e n t
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     R e p l i c a t i o n - d e f i c i e n t
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  R o u t e  o f  A d m i n i s t r a t i o n
    7 . 1     S u b c u t a n e o u s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
       
    7 . 2     P e r c u ta n e o us
        7 . 2 .1  M a rk e t  T re n d s
        7 . 2 .2  M a rk e t  F o r e c a s t
8    Ma r k e t  B r e a ku p  b y  D i s t r ib u t i o n  C h a n n e l
    8 . 1     H o s p i t a l  P h a rm a c y
        8 . 1 .1  M a rk e t  T re n d s
        8 . 1 .2  M a rk e t  F o r e c a s t
    8 . 2     R e t a i l  P h a r m ac y
        8 . 2 .1  M a rk e t  T re n d s
        8 . 2 .2  M a rk e t  F o r e c a s t
Table of     8 . 3     On l i n e  P h a r ma c y
        8 . 3 .1  M a rk e t  T re n d s
        8 . 3 .2  M a rk e t  F o r e c a s t
Contents     8 . 4     O t h e rs        8 . 4 .1  M a rk e t  T re n d s
        8 . 4 .2  M a rk e t  F o r e c a s t
9    Ma r k e t  B r e a ku p  b y  E n d  U se r
    9 . 1     H o s p i t a l s
        9 . 1 .1  M a rk e t  T re n d s
        9 . 1 .2  M a rk e t  F o r e c a s t
    9 . 2     C l i n i c s
        9 . 2 .1  M a rk e t  T re n d s
        9 . 2 .2  M a rk e t  F o r e c a s t
    9 . 3     O t h e rs
        9 . 3 .1  M a rk e t  T re n d s
        9 . 3 .2  M a rk e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht tps : / /www. imarcgroup .com/monkeypox -vacc ine -market / t
oc
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: